Please login to the form below
rocapuldencel-T
This page shows the latest rocapuldencel-T news and features for those working in and with pharma, biotech and healthcare.
Argos hit as kidney cancer immunotherapy fails phase III trial
Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime soon have been dashed after it flunked a pivotal phase III trial. ... Rocapuldencel-T, a personalised immunotherapy that uses individual patients' tumour
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
